New drug shows promise for rare muscle disorder in early trial
NCT ID NCT04004000
First seen Jan 09, 2026 · Last updated May 20, 2026 · Updated 19 times
Summary
This study tested a drug called losmapimod in 14 adults with facioscapulohumeral muscular dystrophy type 1 (FSHD1), a rare genetic condition that causes muscle weakness. The main goal was to see if the drug is safe and tolerable, and to measure changes in certain body markers. The trial was stopped early, but the results help guide future research into treatments for this disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY 1 are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Radboud University Medical Center
Nijmegen, 9101, Netherlands
Conditions
Explore the condition pages connected to this study.